ESR2 and cancer: Possible actions of TSN as an antitumor drug against a variety of cancer types involve inhibition of STAT3, an emerging target for cancer therapy, induction of estrogen receptor β (ERβ) and p53 proteins, and activation of the mitochondrial apoptotic pathway [312,313,314].